Which treatment for hyperprolactinemic females?
This paper has as its first aim the review of the present evidence for risks of chronic hyperprolactinemia as well as benefits and hazards of treatment tools. Among long-term risks, an increased incidence of breast cancer is unlikely while growth of pituitary adenomas occur in a minority. Though control of prolactin secretion can be obtained in most cases, cure of the disease is estimated to be nil with dopaminergic drugs and less than 50% with pituitary surgery. The efficacy of radiotherapy remains questionable. The choice of short- and long-term treatment is discussed according to specific clinical conditions.
D000236:Adenoma / Q000150:complications / Q000601:surgery*; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000209:etiology / Q000628:therapy*; D010053:Ovary / Q000503:physiopathology; D010911:Pituitary Neoplasms / Q000150:complications / Q000601:surgery*; D012306:Risk
D001971:Bromocriptine